University of Chicago

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Chicago sits in the top decile of US sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count).

796 total trials 158 currently recruiting 451 completed early-phase tilt top decile by trial count

University of Chicago: 796 sponsored US clinical trials, 158 recruiting.

University of Chicago sponsors 796 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 451 completed. 67 of these trials are in Phase 3-4 (later-stage) and 293 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 11 trials.

Top-decile sponsor footprint

University of Chicago ranks in the top decile of sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 40/100

451 of 562 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

796 total, page 14 of 16

COMPLETED Phase 3

Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis

NCT00343850

TERMINATED Phase 2

Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer

NCT00347438

COMPLETED NA

Psychotherapy for Intermittent Explosive Disorder

NCT00667212

TERMINATED Phase 4

Treatment of Olfactory Dysfunction in Seasonal Allergic Rhinitis

NCT00361439

COMPLETED NA

Comparison of Two Methods of Negative Pressure Wound Therapy

NCT00724750

COMPLETED

Sleep Disturbances as a Non-Traditional Risk Factor in Chronic Kidney Disease- University of Illinois

NCT00817492

COMPLETED Phase 2

Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer

NCT00468169

COMPLETED Phase 2

N-Acetyl Cysteine in Trichotillomania

NCT00354770

TERMINATED Phase 4

Systemic Steroids Plus Antibiotics in Sleep Apnea Syndrome in Children

NCT00456339

COMPLETED Phase 2

N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence

NCT00332605

COMPLETED NA

Effects of Continuous Airway Pressure on the Ability to Heat and Humidify Air

NCT00338403

TERMINATED NA

The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer

NCT00619242

TERMINATED

Reducing the Risk of Developing Major Depression in Adolescents/Young Adults With Minor Depression/Depression Symptoms

NCT00145951

COMPLETED NA

Cytokine Profiles in Children With Obstructive Sleep Apnea

NCT00456573

TERMINATED Phase 2

Trial of Adalimumab in Progressive Sarcoidosis

NCT00311246

COMPLETED Phase 1

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

NCT00943592

TERMINATED

Early Indicators of Chronic Rejection in Lung Transplant

NCT00449332

COMPLETED Phase 1

Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors

NCT00708773

COMPLETED Phase 2

Efficacy of Naltrexone in Women's Smoking Cessation

NCT00271024

COMPLETED NA

Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery

NCT00406913

COMPLETED Phase 4

Xolair in Patients With Chronic Sinusitis

NCT00117611

COMPLETED

A Study to Tailor Advance Directives

NCT00121004

TERMINATED Phase 4

The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis

NCT00119015

COMPLETED Phase 3

Wireless Capsule Endoscopy in Ulcerative Colitis

NCT00145808

COMPLETED Phase 2

Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients

NCT01172470

COMPLETED Phase 2

Early Directed Physical Therapy in the Management of Mechanically Ventilated Patients in a Medical Intensive Care Unit

NCT00322010

COMPLETED Phase 1

Rapamycin in Advanced Cancers

NCT00707135

COMPLETED Phase 1

Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers

NCT00143741

COMPLETED Phase 3

Follow-up at School-age of Children Who Participated in the Efficacy Study of Nitric Oxide for Premature Infants

NCT00152542

COMPLETED NA

Impact of a Sleep Debt in Middle-Aged and Older Adults

NCT00817700

COMPLETED Phase 3

Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa

NCT00203957

COMPLETED

Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy

NCT00721591

COMPLETED NA

Nasal Ocular Reflexes Contribute to Eye Symptoms

NCT00117832

COMPLETED Phase 2

Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

NCT00519077

TERMINATED Phase 2

Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer

NCT00203931

TERMINATED Phase 2

A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma

NCT00523640

COMPLETED Phase 4

Comparison Study Between Cefdinir & Amoxicilline/Clavulanate in Acute Sinusitis and Assessment of Quality of Life

NCT00147914

COMPLETED Phase 1

Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer

NCT01215500

COMPLETED Phase 1

A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations

NCT00116402

TERMINATED NA

Evaluation of an Intervention on Adherence to Highly Active Antiretroviral Therapy (HAART) in HIV Infected Adults

NCT00203853

COMPLETED Phase 3

Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)

NCT00117572

COMPLETED Phase 1

Study of Rapamycin Plus Ketoconazole in Advanced Cancers

NCT00708591

COMPLETED NA

The Application of Neck Ultrasound in the Assessment of Peripherally Inserted Central Catheter (PICC) Tip Position

NCT00565877

COMPLETED

Pediatric Sleep Questionnaire: Use for Collection of Clinical Data

NCT00203827

COMPLETED

Pediatric Sleep Questionnaire: Normalization and Validation Study

NCT00203840

COMPLETED Phase 3

MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma

NCT00606866

COMPLETED Phase 1

A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer

NCT01187485

TERMINATED NA

Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease

NCT00152620

TERMINATED Phase 3

Treatment for Chronic Depression

NCT00204152

COMPLETED Phase 4

A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment

NCT00145795

← Previous Page 14 of 16 Next →

Phase Distribution

PhaseTrial count
Phase 1 137
Phase 2 156
Phase 3 14
Phase 4 53

What is open in the University of Chicago pipeline

158 recruiting of 796 indexed (20% open); 451 completed (57%).

Phase mix: 67 late (III/IV) vs 293 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (11 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Chicago: open-pipeline peers nationwide

Peers matched on 796 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 14%16%18%20%22% Total trials Recruiting share University of ChicagoDana-Farber Cancer InstituteUniversity of California, San DiegoUniversity of UtahUniversity of Texas Southwestern Medical CenterAcera SurgicalAlign TechnologyAltruBioAlvernia University
University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 796 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

What to do with this University of Chicago page

796 registered trials is a research-attention snapshot, not an endorsement of University of Chicago or any single study.

  • 158 of University of Chicago's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition University of Chicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Chicago pipeline card: 796 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.